financetom
Business
financetom
/
Business
/
YETI's Q4 Earnings to Fall Short of Expectations, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
YETI's Q4 Earnings to Fall Short of Expectations, UBS Says
Feb 7, 2025 12:28 PM

03:07 PM EST, 02/07/2025 (MT Newswires) -- YETI (YETI) is likely to report Q4 earnings that fall short of analyst estimates when the results are unveiled before the opening bell on Thursday, UBS said in an earnings preview.

The firm said Friday it was forecasting Q4 earnings of $0.91 per share for the outdoor products retailer, below the $0.93 consensus of analysts polled by FactSet.

UBS also said sentiment around the stock remains "mixed" as investors are concerned about the impact of tariffs on YETI's bottom line despite its current valuation which offers an "attractive entry point." While the company's management is prioritizing steps to minimize the impact of any tariffs, visibility remains limited given the many moving pieces, UBS said.

The firm said it views the company's valuation alone as not being a meaningful catalyst and that it would remain on the sidelines until there's greater clarity on the company's top and bottom line trajectory.

For 2025, UBS said it was currently estimating net sales growth of 7.4% - in-line with estimates - as well as full-year EPS of $2.90, also in-line with consensus estimates.

UBS has a neutral rating on the stock with a $43 price target.

YETI shares were down 3.1% in recent trading.

Price: 36.23, Change: -1.16, Percent Change: -3.10

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tariffs have cost Volkswagen 'several billions' so far, CEO says
Tariffs have cost Volkswagen 'several billions' so far, CEO says
Sep 8, 2025
* CEO says Porsche brand in 'sandwich' between China, tariffs * Volkswagen in talks with Washington over investment tax breaks * Undecided whether Blume will give up VW or Porsche CEO role (Adds context in paragraph 3-4, CEO comments in paragraphs 7, 10) By Christoph Steitz and Louisa Off MUNICH, Sept 8 (Reuters) - U.S. tariffs have cost Volkswagen, Europe's...
BRIEF-Strathcona Resources Announces Amended And Extended Offer To Acquire Meg Energy Corp
BRIEF-Strathcona Resources Announces Amended And Extended Offer To Acquire Meg Energy Corp
Sep 8, 2025
Sept 8 (Reuters) - STRATHCONA RESOURCES ( STHRF ): * STRATHCONA RESOURCES ( STHRF ) - MEG BOARD DEAL IS UNFAIR TO MEG SHAREHOLDERS AND RESULT OF A BROKEN SALE PROCESS * STRATHCONA RESOURCES LTD. ( STHRF ) ANNOUNCES AMENDED AND EXTENDED OFFER TO ACQUIRE MEG ENERGY CORP. * STRATHCONA RESOURCES LTD ( STHRF ) - AMENDED OFFER EQUATES TO...
AstraZeneca Says Tagrisso Combination Therapy Demonstrates Superior Overall Survival in Late-Stage Trial
AstraZeneca Says Tagrisso Combination Therapy Demonstrates Superior Overall Survival in Late-Stage Trial
Sep 8, 2025
04:27 AM EDT, 09/08/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday that results from a phase 3 trial of Tagrisso plus pemetrexed and platinum-based chemotherapy showed statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival compared with Tagrisso alone in patients with non-small cell lung cancer. The Tagrisso combination therapy showed a median...
Ideaya Biosciences, Partner Say Small Cell Lung Cancer Therapy Shows Promising Early Data
Ideaya Biosciences, Partner Say Small Cell Lung Cancer Therapy Shows Promising Early Data
Sep 8, 2025
04:17 AM EDT, 09/08/2025 (MT Newswires) -- Ideaya Biosciences ( IDYA ) and Hengrui Pharma said Sunday that initial data from a phase 1 trial of the experimental IDE849 small cell lung cancer treatment showed strong overall response and disease control rates across all tested doses and stages of treatment, with only a modest decline in later-line patients, an expected...
Copyright 2023-2026 - www.financetom.com All Rights Reserved